Skip to main content
Michael Tetzlaff, MD, Pathology, Houston, TX

Michael T Tetzlaff MD

Dermatopathology, Anatomic Pathology, Clinical Pathology


Physician

Join to View Full Profile
  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Michael Tetzlaff, MD is a board certified pathologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alaska, and Illinois.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Dermatopathology, 2009 - 2010
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2005 - 2009
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2005

Certifications & Licensure

  • AK State Medical License
    AK State Medical License 2022 - 2026
  • CA State Medical License
    CA State Medical License 2020 - 2026
  • IL State Medical License
    IL State Medical License 2021 - 2026
  • TX State Medical License
    TX State Medical License 2010 - 2025
  • PA State Medical License
    PA State Medical License 2005 - 2010
  • Pathology - Anatomic
    American Board of Pathology Pathology - Anatomic
  • Dermatopathology
    American Board of Pathology Dermatopathology

Publications & Presentations

PubMed

Press Mentions

  • Lichenoid Dermatitis with Mycosis Fungoides Features Linked to Checkpoint Inhibitor Therapy
    Lichenoid Dermatitis with Mycosis Fungoides Features Linked to Checkpoint Inhibitor TherapyJuly 28th, 2019
  • Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma
    Dual Neoadjuvant Checkpoint Blockade Feasible in MelanomaOctober 11th, 2018
  • Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage Three Melanoma
    Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage Three MelanomaOctober 8th, 2018
  • Join now to see all